MENU
Anatomy
Anesthesiology
Biochemistry
Biomedical Informatics
Biophysics
Cell Biology
Clinical Cases
Dentistry
Dermatovenerology
Emergency Medicine
Family Medicine
Forensic Medicine
Gynecology and Obstetrics
Histology and Embryology
History of Medicine
Human Genetics
Hygiene
Infectious Diseases
Internal Medicine
Medical Deontology and Philosophy
Medical Psychology
Microbiology and Immunology
Neurology
Occupational Medicine
Oncology
Ophthalmology
Orthopaedics
Otorhinolaryngology
Pathology
Pathophysiology
Pediatrics
Pharmacology and Experimental Toxicology
Physical and Rehabilitation Medicine
Physiology
Psychiatry
Radiology
Social Medicine
Surgery
Toxicology
Research papers
Clinical research paper
Preclinical research paper
Sponsored articles
Archive » 2012 » 2 » | Archive » Medical field » Fields » Pharmacology and Experimental Toxicology » Archive » Medical field » Fields » Psychiatry » Archive » Medical field » Sponsored articles »

Post-Authorization Safety and Efficacy Study of Escitalopram (Ecytara®) in the Treatment of Depression and Anxiety Disorders

 
Abstract:

This post is also available in: enEnglish slSlovenščina (Slovenian)

BACKGROUNDS. Depression is the most common mental disorder and is a serious mental illness. It is a mental disorder that pose a real problem to the public health care system. Early diagnosis and treatment is instrumental in a relatively good management and control of disease. Selective serotonin reuptake inhibitors are first-line drugs for depression treatment according to guidelines. METHODS. We conducted a post-authorisation study in which 389 patients with depression and anxiety disorders received escitalopram (Ecytara®). After eight weeks of treatment (average dose of 11.6 mg), 296 patients were included in the analysis of the effectiveness. RESULTS. The symptom expression was reduced in 98 % of patients. Due to symptom improvement, 63 % of patients became only marginally ill or symptom-free. Escitalopram was well tolerated by patients. During monitoring, medicine-related adverse reactions were noted in 10.7 % of patients, while at the end of monitoring the number fell to 1.1 %. The post-authorisation study showed that the most frequent adverse reaction was nausea with frequency of 4.1 %. CONCLUSIONS. Escitalopram is efficient and safe antidepressant and is suitable for depression and anxiety disorder treatment.

Authors:
Kapš Peter, Zupanc Nina

Keywords:
depression, anxiety disorders, safety, efficacy, escitalopram

Cite as:
Med Razgl. 2012; 51: 229–34.
© 2021 Društvo Medicinski razgledi | Na vrh strani / To top ↑